Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Orion Corporation maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 9 pending office actions. These matters are distributed across 9 distinct examiners, meaning the count of examiners matches the count of pending cases. This distribution suggests a broad spread of oversight across the USPTO for the company's current filings.
The prosecution activity spans 5 distinct art units, which reflects a range of technical classifications within the biotechnology sector. PARK, HAEJIN S is the busiest examiner for the portfolio, though this individual is responsible for only 1 pending office action. This low concentration of work under an individual examiner highlights the decentralized nature of the company's workload.
Practitioners managing the pending office actions face a variety of perspectives across the 5 distinct art units. Because no individual examiner handles more than 1 pending office action, prosecution strategies may need to be tailored to the specific preferences of each of the distinct examiners involved in the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 6 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.0% | +38.4% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.6% | +53.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | — |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | — |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | — |
| 18573360 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | SAMSELL, RILLA MARIE | — |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | — |
| 17796691 | STABLE PHARMACEUTICAL COMPOSITIONS OF ROPINIROLE | HUANG, GIGI GEORGIANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | — |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | — |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | — |
| 18708157 | CYP11A1 INHIBITORS | MOU, LIYUAN | — |
| 18704868 | SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11 A1 INHIBITOR | RAMACHANDRAN, UMAMAHESWARI | — |
| 18696317 | CYP11A1 INHIBITOR FOR USE IN THE TREATMENT OF PROSTATE CANCER | SZNAIDMAN, MARCOS L | — |
| 18548489 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1628 | 1 |
| 1624 | 1 |
| 1622 | 1 |
| 1675 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | 1614 | §103§112Other | Final Rejection | — | Pending | Jun 13, 2025 |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | — | §103§112Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | — | §103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18708157 | CYP11A1 INHIBITORS | MOU, LIYUAN | — | §103§112DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18704868 | SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11 A1 INHIBITOR | RAMACHANDRAN, UMAMAHESWARI | — | §103DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18696317 | CYP11A1 INHIBITOR FOR USE IN THE TREATMENT OF PROSTATE CANCER | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18573360 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | SAMSELL, RILLA MARIE | 1624 | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18548489 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112DPOther | Final Rejection | — | Pending | Aug 30, 2023 |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | 1675 | §102§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 17796691 | STABLE PHARMACEUTICAL COMPOSITIONS OF ROPINIROLE | HUANG, GIGI GEORGIANA | 1613 | §102§103 | Final Rejection | — | Pending | Aug 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial